This pattern also aligns with potential CH-favoring changes in DLBCL treatment, notably the widespread adoption of rituximab-based regimens and increased use of dose-dense therapies such as dose-adjusted EPOCH (2, 32), which often requires prophylactic G-CSF (33). This evidence concerns the gene C4B and diffuse large B-cell lymphoma.